Literature DB >> 32290899

Microscale Collagen and Fibroblast Interactions Enhance Primary Human Hepatocyte Functions in Three-Dimensional Models.

David A Kukla1, Alexandra L Crampton2, David K Wood2, Salman R Khetani1.   

Abstract

Human liver models that are three-dimensional (3D) in architecture are indispensable for compound metabolism/toxicity screening, to model liver diseases for drug discovery, and for cell-based therapies; however, further development of such models is needed to maintain high levels of primary human hepatocyte (PHH) functions for weeks to months. Therefore, here we determined how microscale 3D collagen I presentation and fibroblast interaction affect the longevity of PHHs. High-throughput droplet microfluidics was utilized to generate reproducibly sized (∼300-μm diameter) microtissues containing PHHs encapsulated in collagen I ± supportive fibroblasts, namely, 3T3-J2 murine embryonic fibroblasts or primary human hepatic stellate cells (HSCs); self-assembled spheroids and bulk collagen gels (macrogels) containing PHHs served as controls. Hepatic functions and gene expression were subsequently measured for up to 6 weeks. We found that microtissues placed within multiwell plates rescued PHH functions at 2- to 30-fold higher levels than spheroids or macrogels. Further coating of PHH microtissues with 3T3-J2s led to higher hepatic functions than when the two cell types were either coencapsulated together or when HSCs were used for the coating instead. Importantly, the 3T3-J2-coated PHH microtissues displayed 6+ weeks of relatively stable hepatic gene expression and function at levels similar to freshly thawed PHHs. Lastly, microtissues responded in a clinically relevant manner to drug-mediated cytochrome P450 induction or hepatotoxicity. In conclusion, fibroblast-coated collagen microtissues containing PHHs display high hepatic functions for 6+ weeks and are useful for assessing drug-mediated CYP induction and hepatotoxicity. Ultimately, microtissues may find utility for modeling liver diseases and as building blocks for cell-based therapies.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32290899      PMCID: PMC7284102          DOI: 10.3727/105221620X15868728381608

Source DB:  PubMed          Journal:  Gene Expr        ISSN: 1052-2166


  43 in total

Review 1.  The application of engineered liver tissues for novel drug discovery.

Authors:  Christine Lin; Kimberly R Ballinger; Salman R Khetani
Journal:  Expert Opin Drug Discov       Date:  2015-04-03       Impact factor: 6.098

2.  One step fabrication of hydrogel microcapsules with hollow core for assembly and cultivation of hepatocyte spheroids.

Authors:  Christian Siltanen; Michalitsa Diakatou; Jeremy Lowen; Amranul Haque; Ali Rahimian; Gulnaz Stybayeva; Alexander Revzin
Journal:  Acta Biomater       Date:  2017-01-06       Impact factor: 8.947

3.  A human liver microphysiology platform for investigating physiology, drug safety, and disease models.

Authors:  Lawrence A Vernetti; Nina Senutovitch; Robert Boltz; Richard DeBiasio; Tong Ying Shun; Albert Gough; D Lansing Taylor
Journal:  Exp Biol Med (Maywood)       Date:  2015-07-22

Review 4.  Microengineered liver tissues for drug testing.

Authors:  Salman R Khetani; Dustin R Berger; Kimberly R Ballinger; Matthew D Davidson; Christine Lin; Brenton R Ware
Journal:  J Lab Autom       Date:  2015-01-23

5.  Integrated in vitro models for hepatic safety and metabolism: evaluation of a human Liver-Chip and liver spheroid.

Authors:  Alison J Foster; Bhavik Chouhan; Sophie L Regan; Helen Rollison; Sara Amberntsson; Linda C Andersson; Abhishek Srivastava; Malin Darnell; Jonathan Cairns; Stanley E Lazic; Kyung-Jin Jang; Debora B Petropolis; Konstantia Kodella; Jonathan E Rubins; Dominic Williams; Geraldine A Hamilton; Lorna Ewart; Paul Morgan
Journal:  Arch Toxicol       Date:  2019-03-26       Impact factor: 5.153

6.  Zonation of acetaminophen metabolism and cytochrome P450 2E1-mediated toxicity studied in isolated periportal and perivenous hepatocytes.

Authors:  I Anundi; T Lähteenmäki; M Rundgren; P Moldeus; K O Lindros
Journal:  Biochem Pharmacol       Date:  1993-03-24       Impact factor: 5.858

Review 7.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

Authors:  Ulrich M Zanger; Matthias Schwab
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

8.  Controlled assembly of heterotypic cells in a core-shell scaffold: organ in a droplet.

Authors:  Qiushui Chen; Stefanie Utech; Dong Chen; Radivoje Prodanovic; Jin-Ming Lin; David A Weitz
Journal:  Lab Chip       Date:  2016-04-21       Impact factor: 6.799

9.  Cellular imaging predictions of clinical drug-induced liver injury.

Authors:  Jinghai J Xu; Peter V Henstock; Margaret C Dunn; Arthur R Smith; Jeffrey R Chabot; David de Graaf
Journal:  Toxicol Sci       Date:  2008-06-03       Impact factor: 4.849

10.  Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease.

Authors:  Catherine C Bell; Delilah F G Hendriks; Sabrina M L Moro; Ewa Ellis; Joanne Walsh; Anna Renblom; Lisa Fredriksson Puigvert; Anita C A Dankers; Frank Jacobs; Jan Snoeys; Rowena L Sison-Young; Rosalind E Jenkins; Åsa Nordling; Souren Mkrtchian; B Kevin Park; Neil R Kitteringham; Christopher E P Goldring; Volker M Lauschke; Magnus Ingelman-Sundberg
Journal:  Sci Rep       Date:  2016-05-04       Impact factor: 4.379

View more
  3 in total

1.  Bioengineering of the liver.

Authors:  Alberto Redaelli; Mian Long
Journal:  APL Bioeng       Date:  2022-04-01

2.  Assessing the compatibility of primary human hepatocyte culture within porous silk sponges.

Authors:  David A Kukla; Whitney L Stoppel; David L Kaplan; Salman R Khetani
Journal:  RSC Adv       Date:  2020-10-12       Impact factor: 4.036

Review 3.  Physiologically relevant microsystems to study viral infection in the human liver.

Authors:  Dennis McDuffie; David Barr; Ashutosh Agarwal; Emmanuel Thomas
Journal:  Front Microbiol       Date:  2022-09-28       Impact factor: 6.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.